However, this application may be well suited for the detection of β2M in the serum of cancer patients with elevated β2M serum levels, which have been reported in prostate cancer, Hodgkin lymphoma, and diffuse large B-cell lymphoma patients. This evidence concerns the gene B2M and prostate carcinoma.